摘要
目的 :探讨SDZPSC 833和维拉帕米 (Verapamil,VER)对MMC体外增敏作用。方法 :以人宫颈癌Hela细胞和耐药亚系Hela/MMC细胞为材料 ,观察了PSC 833和VER对MMC体外增敏作用。结果 :无毒剂量的PSC 833和VER (1～ 3μg/ml)可显著增加MMC的细胞毒作用且可基本克服Hela/MMC细胞对MMC 5倍的耐药 ,3 H_TdR实验表明 ,VER或PSC 833与MMC联用可增加MMC对宫颈癌细胞DNA合成的抑制 ,且PSC作用强于VER ,光镜和电镜下形态学观察 ,联合用药组细胞呈明显退行性变。结论 :无毒剂量的PSC 833和VER体外能基本逆转Heal/MMC细胞对MMC的耐药性 ,且PSC 833作用强于VER ,PSC 833作为耐药修饰剂可望用于宫颈癌化疗 ,其临床应用前景优于VER。
Objective:To determine the reversion of mitomycin(MMC) resistance by SDZ PSC 833 and cerapamil (VER) in human cervical in vitro.Methods:The reversion of mitomycin of resistance by SDZ PSC 833 or VER was detected for human cervical cancar cell (Hela) and its resistant subline Hela/MMC in virto.Results:Both nontoxin doses of PSC 833 and VER might enhance the cytotoxicity of MMC in Hela and Hela/MMC3 μg/ml of PSC 833 and VER could result in almost complete or partial reversion of MMC-resisistance of Hela/MMC 3H-TdR incorporation test indicated that PSC 833 or VER enhanced the inhibition of DNA synthesis in Hela and Hela/MMC cell.Moreover the effect of PSC 833 on reversing drug restance was better than VER in vitro.Conclusions:PSC 833 and VER can overcome mitomycin resistance of Hela/MMC in vitro.PSC 833 will be a better candidate for reversing multidrug resistant than verapamil in clinic.
基金
湖北省教委资助
关键词
子宫颈肿瘤
药物耐受性
丝裂霉素C
cervix neoplasms
mitomycin
drug resistance
reversion
cyclosporin
verapamil
